MRX-2843
Drug timelines are a Plus or Pro feature.
3 regulatory and trial events tracked for MRX-2843, covering 2026-01-08 to 2026-03-31. Get the full timeline:
Most recent: Clinical Trial Update: MRX-2843 and Osimertinib for the Treatment of Advanced EGFR Mutant Non-small Cell Lung Cancer [Phase 1]